Convergence of human genetics and animal studies: Gene therapy for X-linked retinoschisis

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 8, 2015, Pages 1-13

  Bush, Ronald A ^a   Wei, Lisa L ^b   Sieving, Paul A ^b  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; RETINOSCHISIN;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CYST; CYTOLOGY; DISEASE SEVERITY; ELECTRORETINOGRAPHY; GENE REPLACEMENT THERAPY; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN GENETICS; MUTATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHENOTYPE; PROTEIN EXPRESSION; RETINOSCHISIS; ANIMAL; DISEASE COURSE; DISEASE MODEL; FEMALE; GENETIC DISEASES, X-LINKED; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; MALE; MEDICAL GENETICS; MOUSE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RARE DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME;

ANIMALIA; MUS;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ELECTRORETINOGRAPHY; FEMALE; GENETIC DISEASES, X-LINKED; GENETIC PREDISPOSITION TO DISEASE; GENETIC THERAPY; GENETICS, MEDICAL; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUTATION; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; RARE DISEASES; RETINOSCHISIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84938678786     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a017368     Document Type: Article

References (62)

1. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80: 9831–9836.
2. Apushkin MA, Fishman GA. 2006. Use of dorzolamide for patients with X-linked retinoschisis. Retina 26: 741–745.
3. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, et al. 2008. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358: 2231–2239.
4. Balaggan KS, Ali RR. 2012. Ocular gene delivery using lentiviral vectors. Gene Ther 19: 145–153.
5. Bennett J, Duan D, Engelhardt JF, Maguire AM. 1997. Realtime, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Invest Ophthalmol Vis Sci 38: 2857–2863.
6. Berns KI, Giraud C. 1996. Biology of adeno-associated virus. Curr Top Microbiol Immunol 218: 1–23.
7. Bowles K, Cukras C, Turriff A, Sergeev Y, Vitale S, Bush RA, Sieving PA. 2011. X-linked retinoschisis: RS1 mutation severity and age affect the ERG phenotype in a cohort of 68 affected male subjects. Invest Ophthalmol Vis Sci 52: 9250–9256.
8. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A, Stout JT, Macko J, et al. 2006. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial. Hum Gene Ther 17: 167–176.
9. Chevez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C, Hurwitz MY, Hurwitz RL. 2005. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 23: 7927–7935.
10. Dalkara D, Kolstad KD, Guerin KI, Hoffmann NV, Visel M, Klimczak RR, Schaffer DV, Flannery JG. 2011. AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. Mol Ther 19: 1602–1608.
11. Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, Flannery JG, Schaffer DV. 2013. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 5: 189ra176.
12. Daya S, Berns KI. 2008. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21: 583–593.
13. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA. 2003. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9: 1306– 1312.
14. Eksandh LC, Ponjavic V, Ayyagari R, Bingham EL, Hiriyanna KT, Andreasson S, Ehinger B, Sieving PA. 2000. Phenotypic expression of juvenile X-linked retinoschisis in Swedish families with different mutations in the XLRS1 gene. Arch Ophthalmol 118: 1098–1104.
15. George ND, Yates JR, Moore AT. 1995. X linked retinoschisis. Br J Ophthalmol 79: 697–702.
16. Ghajarnia M, Gorin MB. 2007. Acetazolamide in the treatment of X-linked retinoschisis maculopathy. Arch Ophthalmol 125: 571–573.
17. Grayson C, Reid SN, Ellis JA, Rutherford A, Sowden JC, Yates JR, Farber DB, Trump D. 2000. Retinoschisin, the X-linked retinoschisis protein, is a secreted photoreceptor protein, and is expressed and released by Weri-Rb1 cells. Hum Mol Genet 9: 1873–1879.
18. Haas J. 1898. Ueber das zusammenvorkommen von veraenderungen der retina und choroidea. Arch Augenheilkd 37: 343–348.
19. Hauswirth W, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon T, Boye SL, Flotte TR, Byrne B, et al. 2008. Phase I trial of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Shortterm results. Hum Gene Ther 0: 081015093227032.
20. Ikeda F, Iida T, Kishi S. 2008. Resolution of retinoschisis after vitreous surgery in X-linked retinoschisis. Ophthalmology 115: 718–722 e711.
21. Jablonski MM, Dalke C, Wang X, Lu L, Manly KF, Pretsch W, Favor J, Pardue MT, Rinchik EM, Williams RW, et al. 2005. An ENU-induced mutation in Rs1h causes disruption of retinal structure and function. Mol Vis 11: 569– 581.
22. Kaludov N, Handelman B, Chiorini JA. 2002. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther 13: 1235–1243.
23. Kaplan J, Pelet A, Hentati H, Jeanpierre M, Briard ML, Journel H, Munnich A, Dufier JL. 1991. Contribution to carrier detection and genetic counselling in X linked retinoschisis. J Med Genet 28: 83–388.
24. Kjellstrom S, Bush RA, Zeng Y, Takada Y, Sieving PA. 2007. Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: Long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci 48: 3837–3845.
25. Machida S, Kondo M, Jamison JA, Khan NW, Kononen LT, Sugawara T, Bush RA, Sieving PA. 2000. P23H rhodopsin transgenic rat: Correlation of retinal function with histopathology. Invest Ophthalmol Vis Sci 41: 3200–3209.
26. MacLachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, Malatos S, Dufresne E, Morris J, Calcedo R, et al. 2011. Preclinical safety evaluation of AAV2-sFLT01—A gene therapy for age-related macular degeneration. Mol Ther 19: 326–334.
27. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, et al. 2008. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358: 2240–2248.
28. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S, et al. 2009. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374: 1597–1605.
29. Mann I, MacRae A. 1938. Congenital vascular veils in the vitreous. Br J Ophthalmol 22: 1–10.
30. Min SH, Molday LL, Seeliger MW, Dinculescu A, Timmers AM, Janssen A, Tonagel F, Tanimoto N, Weber BH, Molday RS, et al. 2005. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of X-linked juvenile retinoschisis. Mol Ther 12: 644–651.
31. Molday LL, Hicks D, Sauer CG, Weber BH, Molday RS. 2001. Expression of X-linked retinoschisis protein RS1 in photoreceptor and bipolar cells. Invest Ophthalmol Vis Sci 42: 816–825.
32. Molday RS, Kellner U, Weber BH. 2012. X-linked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res 31: 195–212.
33. Mori S, Wang L, Takeuchi T, Kanda T. 2004. Two novel adeno-associated viruses from cynomolgus monkey: Pseudotyping characterization of capsid protein. Virology 330: 375–383.
34. Pang J, Boye SE, Lei B, Boye SL, Everhart D, Ryals R, Umino Y, Rohrer B, Alexander J, Li J, et al. 2010. Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Ther 17: 815–826.
35. Park TK, Wu Z, Kjellstrom S, Zeng Y, Bush RA, Sieving PA, Colosi P. 2009. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 16: 916–926.
36. Peachey N, Fishman G, Derlacki D, Brigell M. 1987. Psychophysical and electroretinographic findings in X-linked juvenile retinoschisis. Arch Ophthalmol 105: 513–516.
37. Petrs-Silva H, Dinculescu A, Li Q, Min SH, Chiodo V, Pang JJ, Zhong L, Zolotukhin S, Srivastava A, Lewin AS, et al. 2009. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 17: 463–471.
38. Petrs-Silva H, Dinculescu A, Li Q, Deng WT, Pang JJ, Min SH, Chiodo V, Neeley AW, Govindasamy L, Bennett A, et al. 2011. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 19: 293–301.
39. Prenner JL, Copone A Jr, Ciaccia S, Takada Y, Sieving PA, Trese MT. 2006. Congenetital X-linked retinoschisis classification system. Retina 26: S61–S64.
40. Reid SN, Akhmedov NB, Piriev NI, Kozak CA, Danciger M, Farber DB. 1999. The mouse X-linked juvenile retinoschisis cDNA: Expression in photoreceptors. Gene 227: 257–266.
41. Reid SN, Yamashita C, Farber DB. 2003. Retinoschisin, a photoreceptor-secreted protein, and its interaction with bipolar and muller cells. J Neurosci 23: 6030–6040.
42. Sauer CG, Gehrig A, Warneke-Wittstock R, Marquardt A, Ewing CC, Gibson A, Lorenz B, Jurklies B, Weber BH. 1997. Positional cloning of the gene associated with Xlinked juvenile retinoschisis. Nat Genet 17: 164–170.
43. Sergeev YV, Caruso RC, Meltzer MR, Smaoui N, MacDonald IM, Sieving PA. 2010. Molecular modeling of retino schisin with functional analysis of pathogenic mutations from human X-linked retinoschisis. Hum Mol Genet 19: 1302–1313.
44. Sergeev YV, Vitale S, Sieving PA, Vincent A, Robson AG, Moore AT, Webster AR, Holder GE. 2013. Molecular modeling indicates distinct classes of missense variants with mild and severe XLRS phenotypes. Hum Mol Genet 22: 4756–4767.
45. Sieving PA, Yashar BM, Ayyagari R. 2000. Juvenile retinoschisis: A model for diagnostic testing of X-linked ophthalmic disease. Trans Am ophthalmol soc 1999;v97: 451–464. Am J Ophthalmol 129: 833.
46. Simonelli F, Cennamo G, Ziviello C, Testa F, de Crecchio G, Nesti A, Manitto MP, Ciccodicola A, Banfi S, Brancato R, et al. 2003. Clinical features of X linked juvenile retinoschisis associated with new mutations in the XLRS1 gene in Italian families. Br J Ophthalmol 87: 1130–1134.
47. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S, Marshall K, Banfi S, Surace EM, et al. 2010. Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18: 643–650.
48. Song JC, McDonnell PJ, Gordon EM, Hall FL, Anderson WF. 2003. Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring. Hum Gene Ther 14: 306–309.
49. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438–1445.
50. Summerford C, Bartlett JS, Samulski RJ. 1999. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 5: 78–82.
51. Takada Y, Fariss RN, Tanikawa A, Zeng Y, Carper D, Bush R, Sieving PA. 2004. A retinal neuronal developmental wave of retinoschisin expression begins in ganglion cells during layer formation. Invest Ophthalmol Vis Sci 45: 3302– 3312.
52. The Retinal Consortium. 1998. Functional implications of the spectrum of mutations found in 234 cases with X-linked juvenile retinoschisis. The Retinoschisis Consortium. Hum Mol Genet 7: 1185–1192.
53. Vandenberghe LH, Auricchio A. 2012. Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther 19: 162–168.
54. Vijayasarathy C, Gawinowicz MA, Zeng Y, Takada Y, Bush RA, Sieving PA. 2006. Identification and characterization of two mature isoforms of retinoschisin in murine retina. Biochem Biophys Res Commun 349: 99–105.
55. Vijayasarathy C, Takada Y, Zeng Y, Bush RA, Sieving PA. 2007. Retinoschisin is a peripheral membrane protein with affinity for anionic phospholipids and affected by divalent cations. Invest Ophthalmol Vis Sci 48: 991– 1000.
56. Vincent A, Robson AG, Neveu MM, Wright GA, Moore AT, Webster AR, Holder GE. 2013. A phenotype-genotype correlation study of X-linked retinoschisis. Ophthalmology 120: 1454–1464.
57. Vogel WF, Abdulhussein R, Ford CE. 2006. Sensing extracellular matrix: An update on discoidin domain receptor function. Cell Signal 18: 1108–1116.
58. Weber BH, Schrewe H, Molday LL, Gehrig A, White KL, Seeliger MW, Jaissle GB, Friedburg C, Tamm E, Molday RS. 2002. Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc Natl Acad Sci 99: 6222–6227.
59. Wilczek M. 1935. Ein der netzhautspaltung (retinoschisis) mit einer offnung. Zeit Augenhlkd 85: 105–116.
60. Wu WW, Molday RS. 2003. Defective discoidin domain structure, subunit assembly, and endoplasmic reticulum processing of retinoschisin are primary mechanisms responsible for X-linked retinoschisis. J Biol Chem 278: 28139–28146.
61. Zeng Y, Takada Y, Kjellstrom S, Hiriyanna K, Tanikawa A, Wawrousek E, Smaoui N, Caruso R, Bush RA, Sieving PA. 2004. RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. Invest Ophthalmol Vis Sci 45: 3279–3285.
62. /Y mice but no therapeutic effect of carbonic anhydrase inhibition. Vet Ophthalmol 15: 123–133.